Molecular glue degraders (MGDs) promote the proximity of target proteins to E3 ubiquitin ligases, enabling degradation of previously "undruggable" proteins. VAV1-targeting MGDs, like MRT6160, show promise in treating immunological diseases by reducing inflammation and autoimmune responses. Our integrated platform uses advanced in vitro assays to explore these MGDs, including complex detection, intracellular protein interaction analysis, and degradation studies. It also evaluates T and B cell activities and cytokine profiles. By addressing challenges such as complex formation and selectivity, our platform provides a universal solution for discovering and optimizing MGDs with broad therapeutic potential.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
